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INTRODUCTION
Asthma is defined by characteristic features such as airway 
hyper-responsiveness (AHR), reversible airflow obstruction, 
and paroxysmal cough, dyspnea, and wheezing, which are as-
sociated with airway inflammation.
1 Therefore, it is not a disease 
entity, but a syndrome caused by a variety of etiologic agents. 
Because the clinical features of asthma and responses to anti-
asthma drugs are similar regardless of cause, most patients are 
treated with the same drugs under the same diagnostic name 
of asthma. However, etiology-based specific treatments have 
long been given, such as avoidance of offending allergens and 
allergen-specific immunotherapy when specific allergens have 
been identified. Moreover, with advances in genetics, the asso-
ciation of HLA-DPB*0301 or cysteinyl leukotriene receptor 1 
promotor-634C>T and the necessity for leukotriene receptor an-
tagonists has been identified in patients with aspirin-intolerant 
asthma.
2 Thus, treatments tailored for individuals have gained 
the attention of clinicians. Although it is premature to apply such 
tailored gene-analysis treatments in general practice, differen-
tial treatment according to sex can be easily introduced because 
genetically determined sex can be identified without the need 
for a gene analysis. In 2003, Osman
3 mentioned sex-specific 
treatments in patients with asthma. However, few systematic re-
views of studies on this issue have been reported so far.
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SEX DIFFERENCES IN ASTHMA PREVALENCE
The prevalence of asthma is higher in males than in females 
before adolescence, but this trend is reversed after adoles-
cence.
3-5 In 1977, Wormald
6 reported that the incidence of asth-
ma with a positive response to skin prick tests using house dust 
mite allergens was three times higher in males before the age of 
10 years, but it changed to 1.5 times and 1.6 times higher in fe-
males in their third and fourth decades (child bearing years), 
respectively, and was higher again in males in their fifth decade 
(Figure). A cross-sectional analysis of the data of the European 
Community Respiratory Health Survey by de Marco et al.
7, con-
ducted in 2000 with more than 18,000 subjects in 16 countries, 
found that the incidence of asthma was 0.56 times lower in fe-
males at the age of 5–10 years but increased in females after ad-
olescence, and it was 5.91 times higher in females after their 
fourth decade; furthermore, this trend was observed in all 16 
countries. Osman et al.
8 also reported in 2007 an analysis of more 
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than 260,000 asthmatic patients retrieved from the General 
Practice Research Database which showed that the prevalence 
of asthma per 100 population was 9.8 for males and 7.3 for fe-
males at the age of 5 years, 6.7 and 6.7 at 15 years, 2.9 and 3.6 at 
25 years, 2.3 and 3.0 at 35 years, 1.8 and 2.9 at 45 years, and 2.3 
and 3.2 at 55 years, respectively, suggesting that the sex ratio re-
verses after adolescence. They also reported a similar trend in 
patients with allergic rhinitis. Similarly, Poulos et al.
9 reported 
in 2007 that the hospital admission rates for urticaria, angioede-
ma, and anaphylaxis were higher in boys than in girls among 
children aged less than 15 years, whereas those rates were higher 
in females than in males among those aged 15 years and older.
This reversal in sex ratio after puberty is not caused by in-
creased loss of established asthma in boys, but by late incidence 
of asthma among girls.
4,10 The sex difference in the prevalence 
of asthma is reflected in the sex difference in the hospitalization 
rate and asthma severity.
4 The reasons for the higher preva-
lence of asthma in boys may be that their airways develop rela-
tively slowly compared with lung volume (dysanapsis)
3,4 and 
are easily sensitized to indoor allergens such as house dust 
mites and cat dander,
11 whereas girls and young women tend to 
be treated after their asthma becomes aggravated (Yentl syn-
drome).
3,4 Actually, the sex difference begins during gestation; 
the lung matures more slowly and surfactant is produced later 
in the male than in the female fetus.
12 Consequently, male neo-
nates tend to have lower specific airway conductance than do 
female neonates.
In adults, because the airway caliber and lung function of 
males are greater than those of females, a smaller airway caliber 
in females may contribute to the reversal of the sex ratio for asth-
ma prevalence after puberty.
7 Because airway resistance is in-
versely proportionate to the fourth power of airway diameter, 
airway resistance easily increases when airway caliber is small, 
and CO2 retention in blood may occur in females due to the small 
airway caliber even when the degree of airflow obstruction is not 
as severe although frank ventilatory failure generally occurs 
when forced expiratory volume in 1 second (FEV1) is ≤25% dur-
ing an asthma attack.
13 Some genetic polymorphisms are asso-
ciated with asthma in females and not in males, such as cytotox-
ic T lymphocyte-associated 4 receptor (+49 A/G), cyclooxygen-
ase-2 (-165 G/C), defensin β-1, toll-like receptor 4, and estrogen 
receptor α.
12 In addition to these genetic, anatomical, and phys-
iological differences, apparent immunological differences must 
exist between the sexes because not only allergic asthma,
6 but 
also other allergic diseases,
8,9 occur more frequently in females 
after puberty, as mentioned above. Moreover, females are more 
sensitive to environmental factors such as smoking, cooking gas, 
ozone, and pets, and body mass index (BMI) is closely related 
to asthma and atopy in women.
4 Sex hormones may play an 
important role in this sex difference.
 SEX HORMONES AND ASTHMA
The immunological system interacts with the endocrine sys-
tem. In general, female sex hormones aggravate asthma and 
other allergic diseases, whereas male sex hormones suppress 
such diseases.
3 Females seem to be born with a Th2 bias, as hu-
mans naturally tend to shift to Th2 to prevent mothers from re-
jecting their fetuses during pregnancy, and immunity becomes 
mature in a Th2-suppressing manner following exposure to in-
fections after birth (the so-called hygiene hypothesis).
Women who reached menarche before the age of 12 years have 
a 2.08-fold higher risk of asthma after puberty compared with 
those who reached menarche after the age 12 years.
14 During 
the menstrual cycle, skin-test responses to allergens,
15,16 adenos-
ine-AHR,
17 and exhaled nitric oxide level
16 vary according to the 
levels of sex hormones, and these responses are abolished by the 
use of oral contraceptives.
16,17 Progesterone
18 and estrogen,
19,20 
the representative female sex hormones, increase the secretion 
of interleukin (IL)-4 and the total IgE level, respectively. How-
ever, progesterone inhibits histamine release from mast cells,
21 
and estrogen induces FoxP3
+ regulatory T (Treg) cells
22,23; thus, 
these hormones do not simply work in one direction. Never-
theless, generally speaking, when the luteal phase, with its in-
creased blood levels of progesterone and estrogen, is suppressed 
by the use of oral contraceptives, associated cyclic changes in 
AHR are inhibited.
17 The risk of asthma decreases by 7% per year 
during oral contraceptive pill use in young women
24 and increas-
es 2.29 times with hormone replacement therapy in postmeno-
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Figure.  Sex differences in asthma prevalence. The ratios of female to male 
patients with asthma and a positive response to skin prick tests using house 
dust mites (HDM) (redrawn from Wormald
6) and in patients who were reported 
to have asthma in the European Community Respiratory Health Survey (ECRHS) 
(redrawn from de Marco et al.
7), and the number of asthma patients per 100 
population for each sex in the General Practice Research Database (redrawn 
from Osman et al.
8).Choi
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pausal women.
25
Male mice have higher numbers of CD4
+/CD25
+ T cells, so it is 
difficult to establish an asthma model using male mice; ovalbu-
min sensitization and challenge in male mice increases the lev-
els of ovalbumin-specific IgE, IL-4, and IL-13 and the numbers 
of CD4
+ T cells, B cells, and eosinophils less remarkably than in 
female mice.
26 During a transient medical castration in men, not 
only serum testosterone, but also CD4
+/CD25
+ T cell numbers 
and CD8
+ T cell interferon (IFN)-γ expression decreases, and 
this is prevented by testosterone replacement.
27 Androgen in-
hibits leukotriene synthesis by controlling the activity of extra-
cellular signal-regulated kinases.
28 Dehydroepiandrosterone 
(DHEA), a weak androgen, which is produced in the adrenal 
gland, has similar activity, so there is a significant relationship 
between the serum level of DHEA sulfate ester (DHEA-S), a 
precursor of DHEA, and the number of IFN-γ-secreting cells.
29 
Because the serum DHEA-S level is relatively low in patients 
with asthma
30 or atopic dermatitis,
31 and because it decreases 
in a dose-dependent manner with the use of inhaled cortico-
steroids,
32 screening tests for serum DHEA-S level may be use-
ful for examining adrenal function and for determining DHEA 
replacement therapy in patients with asthma who are receiving 
inhaled steroid treatment. Testosterone replacement therapy in 
male patients with rheumatoid arthritis and low testosterone 
levels increases CD8
+ T cells and decreases IgM rheumatoid fac-
tor and medication requirements.
3
SEX, OBESITY, AND ASTHMA
Although women are usually under stress to be lean, and their 
greatest concern is eating habits, obesity develops more fre-
quently in women. When obesity is defined as a BMI ≥30 kg/m
2, 
the prevalence of obesity is 24.1% in men and 24.9% in women 
in the United Kingdom, and 28.6% in men and 34.2% in women 
in the United States.
33 Although women must store excess fat for 
reproduction and lactation, the exact mechanism underlying 
the need for excess body weight in women is not well under-
stood; however, lower energy expenditure due to shorter stat-
ure and less fat-free body mass in women must play an impor-
tant role.
34 Estrogen rather decreases appetite and body weight. 
This hormone decreases abdominal and visceral fat, which is 
associated with metabolic syndrome, but it distributes fat to the 
gluteo-femoral area, and this fat is used through lipolysis by li-
poprotein lipase activity during lactation.
Recently, the prevalence of asthma and obesity have simulta-
neously increased, so it is presumed that obesity may be one of 
the causes of asthma.
35 Camargo et al.
36 reported in 1999 that the 
risk for developing asthma was 2.7 times higher in obese wom-
en and 2.5 times higher when body weight had increased by 25 
kg at the 4-year follow-up after the age of 18 years. The mecha-
nisms by which obesity affects asthma include 1) mechanical 
factors such as lower lung volume and compliance and smaller 
diameter of the peripheral airways, 2) comorbidities such as gas-
troesophageal reflux disease (GERD), 3) systemic inflammation 
caused by fat-cell-secreting adipokines including IL-6, tumor 
necrosis factor (TNF)-α and eotaxin, 4) a decrease in adiponec-
tin, an obesity hormone with an anti-inflammatory effect, 5) an 
increase in AHR by leptin, which has a similar structure as IL-6, 
and 6) increased oxidative stress.
37,38 Unlike patients with Th2-
mediated asthma, obese asthmatics show unremarkable airway 
inflammation, suggesting a distinct asthma phenotype.
38 Thus, 
these patients may have relative resistance to conventional cor-
ticosteroid therapy,
38,39 and special attention should be paid to 
frequently comorbid GERD.
38 However, Yoo et al.
40 have report-
ed that the prevalence of atopy is higher in obese Korean male 
adolescents. Jeon et al.
41 have documented that the FEV1/forced 
vital capacity (FVC) ratio is significantly lower in obese women 
or during the menstrual period, but unfortunately, they did not 
observe whether obese patients with asthma showed a de-
creased FEV1/FVC ratio during the menstrual period.
Insulin resistance is associated with obesity; diacylglycerol ac-
cumulates in the skeletal muscle and liver and triggers protein 
kinase C activation, with subsequent impairments in insulin 
signalling.
42 Insulin has an anti-inflammatory effect by inhibit-
ing nuclear factor κB and inducing FoxP3
+Treg cells, so insulin 
may affect athma.
23 Despite the observation that sex hormone 
replacement therapy increases the risk of developing postmeno-
pausal asthma in lean women without insulin resistance, it may 
improve asthma in obese postmenopausal women with insulin 
resistance by decreasing body weight and insulin resistance.
FEMALE-SPECIFIC ASTHMA
Perimenstrual (catamenial) asthma
As mentioned above, asthma and allergy markers vary during 
the menstrual cycle according to sex hormone levels,
15-17 and 
perimenstrual asthma occurs in 30–40% of female asthmatics 
during the child-bearing years, regardless of allergy.
23 Recently, 
in a study monitoring daily respiratory symptoms of fertile asth-
matic females during two consecutive menstrual cycles, Pereira 
Vega et al.
43 reported that 59.6% of patients showed premenstru-
al exacerbation of symptoms in at least one of the two cycles, 
but only 22.3% in both cycles. Autoantibodies against sex hor-
mones are also able to induce perimenstrual asthma and mis-
carriage.
44 Since perimenstrual asthma was first described by 
Frank et al.
45 in 1931, numerous studies have reported on this 
type of asthma. During the perimenstrual period, not only ade-
nosine-AHR,
17 but also methacholine-AHR
46 is aggravated, and 
the use of oral contraceptives can prevent such aggravation
17,46 
and improve clinical symptoms.
23
Asthma-related menstrual irregularity
As asthmatics show changes in sex hormones such as a de-
crease in serum DHEA-S level regardless of drug therapy, they Gender-Specific Asthma Treatment AAIR 
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can also have associated menstrual irregularities. In a study at 
seven institutions with approximately 8,000 women of child-
bearing age, Svanes et al.
47 found that the prevalence of men-
strual irregularity was 1.54 times higher in patients with asthma 
and 1.29 times higher in those with allergic rhinitis regardless of 
the use of antiasthmatic medications, and this difference was 
similar at all seven institutions. They suggested that insulin re-
sistance may correlate with both asthma and menstrual irregu-
larity.
Pregnancy
Pregnancy affects asthma and vice versa, including mechani-
cal changes in lung function. The purpose of asthma treatment 
during pregnancy is delivery of a healthy baby, which is an im-
portant goal in addition to those for general asthma. Since the 
considerable number of congenital malformation cases due to 
thalidomide in the 1960s, careful administration of drugs dur-
ing pregnancy has become common sense. Details about this 
issue can be found elsewhere.
48
SEX DIFFERENCES IN THE EFFECTIVENESS OF AND 
ADVERSE REACTIONS TO ASTHMA TREATMENT
Treatment effectiveness
Because a sex difference exists in the prevalence of asthma 
and allergic diseases and sex hormones affect allergic diseases, 
it is postulated that responses to anti-asthmatic drugs differ be-
tween the sexes; however, few investigations have examined this 
issue. Montelukast, but not fluticasone, increases FEV1 in fe-
males more than in males among patients aged 6–17 years with 
asthma.
49 Johnston et al.
50 reported that montelukast prevents 
asthma’s worsening in younger boys aged 2–5 years (odds ratio 
[OR], 0.03; P<0.001) or 6–9 years (OR, 0.27; P=0.028) and in older 
girls aged 10–14 years (OR, 0.17; P=0.001). Such sex differences 
in treatment effectiveness may be mainly attributable to dysan-
aptic lung growth in boys
3,4,51 and female sex hormone after 
menarche, which are associated with more active asthma.
51 BCG 
and DHEA are more effective in female mice than in male mice.
52 
Male mice have a high IFN-γ/IL-5 ratio and low allergen-specif-
ic IgE level, but they develop asthma despite this and may re-
quire treatment to help overcome these conditions. Further-
more, male children have higher theophylline clearance
53 and 
lower drug adherence during asthma exacerbation,
54 but con-
trolling their asthma is relatively easier.
55
Adverse reactions
Adverse drug reactions occur more frequently in females than 
in males. For instance, the rate of a positive skin test to penicil-
lin is 3.2 times higher in females than in males.
56 Additionally, 
as females have a lower drug clearance rate, adverse reactions 
due to theophylline
53 and hypersomnia resulting from first-gen-
eration antihistamines and cetirizine occur more frequently in 
females than males.
57 Asthmatic women using fluticasone dry 
powder inhalers complain of hoarseness and dysphonia more 
frequently than men do.
58 Estrogen inhibits osteoclast prolifera-
tion and bone turnover, so deficiency in this hormone in post-
menopausal women makes them prone to developing steroid-
induced osteoporosis.
59 Testosterone prevents the development 
of osteoporosis by directly acting on osteoblasts or after being 
converted to estrogen by aromatase.
SEX-SPECIFIC ASTHMA TREATMENT
Females
Female-specific asthma including perimenstrual asthma may 
require appropriate therapy such as oral contraceptives. Con-
sidering that asthma and other allergic diseases as well as ad-
verse reactions to drugs occur more frequently in females, it is 
conceivable that DHEA, an androgen with a less virilizing effect, 
could be used as a treatment option for female-specific asthma. 
DHEA reduced the steroid requirement without significant ad-
verse reactions, other than mild acne, in patients with systemic 
lupus erythematosus.
60 A phase IIa clinical trial of an inhalation 
formulation of synthetic DHEA sulfate EPI-12323 (Naturasone) 
found a significant inhibition of allergen-induced late airway 
reactions,
61 suggesting its potential use in clinical practice.
Although DHEA is the crucial precursor for converting both 
testosterone and estrogen, DHEA administration increases cir-
culating androgens in women.
62 T lymphocytes and endotheli-
al cells have high-affinity binding sites for DHEA. A previous 
study demonstrated that DHEA inhibits AHR/airway eosino-
philia and that its effects are related to a decrease in IL-5 con-
centration in mice.
63 DHEA inhibits cell proliferation but main-
tains Th1 bias
64 and may also work through IL-10 production.
65 
Furthermore, the antagonistic action of DHEA against gluco-
corticoid-induced Th2 deviation can probably occur through 
peroxisome proliferator-activated receptor-α.
66 DHEA inhibits 
airway smooth muscle proliferation and airway remodeling by 
inhibiting DNA binding of activator protein (AP)-1, and it may 
produce a steroid-sparing effect by suppressing AP-1-induced 
glucocorticoid resistance.
67 Moreover, DHEA inhibits produc-
tion of TNF-α68 and neutrophilic inflammation,
69 through which 
it exerts a therapeutic effect on severe asthma associated with 
such factors. However, the long-term systemic use of DHEA may 
induce chronic heart failure by deleting ubiquinone through the 
inhibition of glucose 6-phosphate dehydrogenase and hydroxy-
methylglutaryl coenzyme A reductase activities.
70 Therefore, an 
inhaled preparation of DHEA is desirable for patients to avoid 
any unexpected serious adverse reactions.
Males
Serum DHEA-S level significantly correlates with IFN-γ level,
29 
and men have a high serum DHEA-S level. Thus, allergic diseas-
es do not frequently develop in men. However, the therapeutic Choi
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effectiveness of DHEA may be low because an increase in the 
IFN-γ/IL-5 ratio by DHEA is inversely related to serum DHEA-S 
level.
64 In that case, men would require treatment modalities 
that induce Th1 cells more strongly or act through different 
mechanisms. However, clinicians should remember that if the 
dosage of DHEA is excessively high, its therapeutic effect tends 
to decrease.
63 Because the dose of inhaled steroid correlates with 
the degree of decrease in serum DHEA-S level,
32 DHEA replace-
ment therapy would be ideal for asthma treatment in men with 
a decreased DHEA-S level detected through regular monitoring.
CONCLUSIONS
Females are more prone to suffer allergic asthma, to having 
difficulty controlling asthma symptoms, and to showing ad-
verse responses to drugs. As asthma symptoms show cyclic 
changes depending on female hormone levels in many women 
of child-bearing age, the use of contraceptives in women may 
specifically help treat such perimenstrual asthma and severe 
asthma as well. Generally, testosterone seems to suppress asth-
ma, and DHEA, a less virilizing androgen, may be effective for 
treating asthma. Evidence exists for the therapeutic and steroid-
sparing effect of DHEA. However, further studies on the opti-
mal dose and route of DHEA for each sex are needed. Monitor-
ing of the serum DHEA-S level is necessary for patients with 
asthma who are receiving inhaled steroid treatment, and at least 
replacement therapy for patients with a low level of DHEA may 
be helpful for treating their asthma.
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